NCT04447846View on ClinicalTrials.gov

Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 14, 2019

Primary Completion Date

August 16, 2021

Study Completion Date

December 9, 2022

Conditions
Sturge-Weber Syndrome
Interventions
DRUG

Cannabidiol

Initiation of treatment will begin with 5 mg/kg/day given in two divided doses. The dose will be increased by 5 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 20 mg/kg/day given.

Trial Locations (1)

21205

Kennedy Krieger Institute, Baltimore

Sponsors

Collaborators (1)

Jazz Pharmaceuticals
All Listed Sponsors
collaborator

Jazz Pharmaceuticals

INDUSTRY

collaborator

Faneca 66 Foundation

OTHER

lead

Anne Comi, MD

OTHER

NCT04447846 - Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome | Biotech Hunter | Biotech Hunter